Bio-tech startup Cellivate Technologies has secured $1 million in seed funding led by Antler, with additional contributions from Venture Catalysts, Hatcher+, and We Founder Circle.
The investment will be used to boost research and development, enhance production capabilities, and broaden market presence, as stated by Cellivate.
Founded by Viknish Krishnan Kutty, Cellivate focuses on developing innovative solutions for cell culture and biomanufacturing challenges. Key products include advanced microcarriers for scaling up cell growth and a novel cell-based serum aimed at replacing fetal bovine serum.
Market research forecasts that the cell culture market, particularly in microcarriers and serum, will reach $33 billion by 2030.
Cellivate’s advanced microcarriers and cell-based serum alternatives are expected to lower costs, improve efficiency, and address ethical issues in cell culture. These technological advancements could reduce reliance on animal-derived products, as many ingredients traditionally sourced from animals can now be obtained from cells.
